Investors don't buy Lyell's solid tumour Car-T success
The ROR1 data are sketchy, and lung toxicity clouds prospects.
Christmas holiday round-up
As the biotech markets turned bullish the sector’s ups and downs continued.
The ROR1 data are sketchy, and lung toxicity clouds prospects.
As the biotech markets turned bullish the sector’s ups and downs continued.
